Título
Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation
Autor
GABRIELA VAZQUEZ RODRIGUEZ
María del Carmen González Castillo
Antonio de León Rodríguez
Nivel de Acceso
Acceso Abierto
Identificador alterno
doi: https://doi.org/10.1007/s12033-012-9642-4
Materias
Resumen o descripción
"Angiogenesis has been considered an important target for cancer therapy. The inhibition of angiogenesis represents a promising strategy for anti-cancer treatment, tumor growth inhibition, and metastasis. Vasostatin 30 (Vs30), and the 14.1 kDa vasoinhibin (Vi-II-14.1) are two peptides with remarkable anti-tumor and anti-angiogenic effect. The aim of this study was to produce a novel fusion protein between Vs30 and Vi-II-14.1, denominated VS_VI, to obtain a new protein with higher biological activity. The protein fusion genes were cloned into a T7 promoter-based vector, expressed in Escherichia coli BL21-SI and purified by affinity column chromatography. In vitro assays showed that the recombinant fusion protein inhibited rat coronary endothelial cell proliferation at 65.5 % at 10 nM, whereas recombinant Vs30 and Vi-II-14.1 inhibited at 33 and 50.5 % respectively, at the same concentration. The results showed that VS_VI is significantly more active than the Vs30 and Vi-II-14.1 separately. In addition, a practical classification of the vasoinhibins based on the peptide origin and theoretical molecular weight is proposed. This is the first study to produce a new fusion protein derived from Vs30 and Vi-II-14.1, both of them proposed as promising therapeutic agents."
Editor
Humana Press Inc
Fecha de publicación
julio de 2013
Tipo de publicación
Artículo
Versión de la publicación
Versión enviada
Recurso de información
Formato
application/pdf
Relación
&
De Leon Rodriguez, A. Mol Biotechnol (2013) 54: 920. https://doi.org/10.1007/s12033-012-9642-4
Sugerencia de citación
Vazquez Rodriguez, G., Gonzalez, C.
Repositorio Orígen
Repositorio IPICYT
Descargas
388